2m 2m 2m 2m 2m 2m 2m
- $13.7MMarket Cap
- -25.11%1-Year Change
- Scientific & Technical InstrumentsIndustry
AINOS (AIMD)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 77
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Ainos Posts Wider Loss in Fiscal Q2
Biotechnology company Ainos reported its Q2 2025 financial results, marking its first commercial revenue through AI Nose platform partnerships and ongoing VELDONA therapy clinical trials, while experiencing increased operating expenses and cash decline.
08/13/2025, 6:26 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Ainos, Inc., a dual-platform company, focusing artificial intelligence"based smelltech technologies and immune therapeutics. It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data. The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women's health sectors. In addition, it develops VELDONA, a low-dose oral interferon platform for human and animal health applications, targeting rare, autoimmune, and infectious diseases. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in Houston, Texas. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.
Key Executives
- Chun-Hsien Tsai
- Hsin-Liang Lee
- Chih-Heng Lu
Current Ownership Distribution
- Insiders19.6M (96.09%)
- Mutual Funds538,368 (2.63%)
- Institutions261,222 (1.28%)
- Other0 (0.00%)